Article
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Blood - 23 Apr 2009
Pratz Keith W, Cortes Jorge, Roboz Gail J, Rao Niranjan, Arowojolu Omotayo, Stine Adam, Shiotsu Yukimasa, Shudo Aiko, Akinaga Shiro, Small Donald, Karp Judith E, Levis Mark
Abstract excerpt
Internal tandem duplication mutations of FLT3 (FLT3/ITD mutations) are common in acute myeloid leukemia (AML) and confer a poor prognosis. This would suggest that FLT3 is an ideal therapeutic target, but FLT3 targeted therapy has produced only modest benefits in clinical trials. Due to technical obstacles, the assessment of target inhibition in patients treated with FLT3 inhibitors has been limited and generally...
Topics
- Antineoplastic Agents
- Cell Survival
- Cells, Cultured
- Humans
- Leukemia
- Mutation
- Protein Binding
- fms-Like Tyrosine Kinase 3